Equities

Vetoquinol SA

Vetoquinol SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)99.50
  • Today's Change-0.40 / -0.40%
  • Shares traded4.46k
  • 1 Year change+17.20%
  • Beta0.6665
Data delayed at least 15 minutes, as of Mar 28 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Vetoquinol SA is a France-based company that specializes in the research, development, manufacture, marketing and sale of veterinary drugs and products. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The Company markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. It trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.

  • Revenue in EUR (TTM)525.26m
  • Net income in EUR58.83m
  • Incorporated1962
  • Employees2.52k
  • Location
    Vetoquinol SASainte-Anne 34 rue du CheneBp 189, Lure CedexLURE 70204FranceFRA
  • Phone+33 384625555
  • Fax+33 384625556
  • Websitehttps://www.vetoquinol.com/fr
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Euroapi SA1.02bn-189.70m257.69m3.45k--0.27742.600.2529-2.01-2.0110.739.770.60861.384.24---11.34---15.93--16.15---18.63--0.65730.93620.1955--3.87---1,164.67------
Nanobiotix SA0.00-58.78m271.96m101.00---------1.68-1.680.00-1.530.00----0.00-97.14-55.16-411.11-75.16-------89,710.66---6.62-----100.00---21.36---42.16--
Medincell SA10.85m-26.42m274.72m138.00------25.33-1.02-1.020.4086-0.89650.2605--6.8175,853.15-63.46-59.54-115.15-117.3660.4368.38-243.58-451.26---4.291.69--141.788.96-29.04---2.87--
Carbios SA81.00k-29.59m405.78m104.00--2.40--5,009.59-2.49-2.490.006810.060.0004--7.36778.85-15.81-9.39-17.36-10.23-620.99---36,529.63-1,258.36---14.940.2565---33.33-41.05-833.89--99.37--
Guerbet SA760.84m-42.37m424.11m2.84k--1.1420.230.5574-3.41-3.4159.7029.320.76210.57285.94267,994.00-4.321.88-7.202.5979.0375.60-5.672.470.4481-2.150.505948.342.90-1.37-225.98--3.50-10.07
Valneva SE153.71m-101.43m498.83m684.00--3.89--3.25-0.7343-0.73431.110.9240.28432.544.69224,726.60-18.76-15.39-31.44-25.0634.3735.94-65.99-34.951.37-3.570.6195---57.466.3429.21--35.18--
Boiron SA517.36m47.62m583.91m2.81k12.141.058.841.132.742.7429.7931.730.67921.366.57184,705.806.145.087.566.3973.8875.129.047.402.54--0.022548.8717.36-2.8656.44-10.60-19.01-7.22
Abivax SA0.00-92.25m835.39m26.00--7.02-----2.89-2.890.001.890.00----0.00-76.01-55.61-113.62-81.62-----------5.090.3602-------68.89--32.30--
Vetoquinol SA525.26m58.83m1.19bn2.52k20.092.3413.192.264.974.9744.4042.730.82432.145.35208,353.009.236.9511.549.2150.6661.2611.208.631.70--0.030316.183.558.92-23.656.6210.4211.70
Virbac SA1.21bn119.46m2.86bn5.40k23.973.1817.282.3714.1214.12143.10106.420.87941.307.09224,710.408.597.2611.7010.3965.1965.809.768.981.25--0.15596.3414.317.137.78--6.98--
Data as of Mar 28 2024. Currency figures normalised to Vetoquinol SA's reporting currency: Euro EUR

Institutional shareholders

13.85%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 Jan 2024412.30k3.47%
Oddo BHF Asset Management SASas of 29 Feb 2024327.89k2.76%
Invesco Advisers, Inc.as of 31 Jan 2024267.01k2.25%
BNP Paribas Asset Management Europe SASas of 29 Feb 2024177.65k1.50%
The Vanguard Group, Inc.as of 07 Mar 2024135.07k1.14%
Cov�a Finance SASas of 29 Dec 202381.65k0.69%
Danske Bank A/S (Investment Management)as of 29 Feb 202474.06k0.62%
Amundi Asset Management SA (Investment Management)as of 31 Jan 202458.12k0.49%
Janus Henderson Investors UK Ltd.as of 31 Jan 202457.10k0.48%
Fourton Fund Management Co. Ltd.as of 30 Jun 202355.00k0.46%
More ▼
Data from 31 Dec 2023 - 20 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.